COVID-19 Virtual Seminar: Ensuring Wellness in a Changing World
As the initial surge of the COVID-19 pandemic subsides, Massachusetts General Hospital leaders are discussing the transition to strategies for recovery and wellness.
Pradeep Natarajan, MD, MMSc
Pradeep Natarajan, MD, MMSc
Cardiologist
Director, Preventive Cardiology
Assistant Professor of Medicine, Harvard Medical School
Director, Preventive Cardiology
Assistant Professor of Medicine, Harvard Medical School
About Pradeep Natarajan, MD, MMSc
Dr. Natarajan is the Director of Preventive Cardiology at Massachusetts General Hospital. He received his BA in molecular biology with Honors and Phi Beta Kappa in 2004 from the University of California, Berkeley. He received his MD with Alpha Omega Alpha in 2008 from the University of California, San Francisco. He received his MMSc in biomedical informatics in 2015 from Harvard Medical School. Dr. Natarajan completed his internship and residency in internal medicine at the Brigham and Women's Hospital, Harvard Medical School in 2011. He completed his clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, Harvard Medical School in 2015.
Dr. Natarajan researches the genetic drivers of human atherosclerosis using genetic epidemiology, large-scale sequencing studies, digital health, and genotype-driven human investigation. In addition to his research efforts, Dr. Natarajan is a clinical cardiologist focusing on heart attack prevention, cardiovascular risk reduction, premature heart attack, lipid disorders, and cardiovascular genetics based at the MGH Cardiovascular Disease Prevention Center.
To learn more about Dr. Natarajan's research, please visit http://natarajanlab.mgh.harvard.edu.
Departments, Centers, & Programs:
Clinical Interests:
- Preventive cardiology
- Lipid disorders
- Cardiovascular genetics
- Cardiovascular risk reduction
- Coronary artery disease
- Coronary heart disease
- Cardiovascular disease prevention
- Hyperlipidemia
- Familial hypercholesterolemia
- Ischemic heart disease
- Premature Atherosclerosis
Treats:
- Adult
Locations
Cardiovascular Disease Prevention Center
25 New Chardon Street
Suite 301
Boston, MA 02114-4774
Phone: 617-726-1843
Fax: 617-726-2203
Medical Education
- MMSc, Harvard University
- MD, UC San Francisco School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Cardiovascular Disease, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Atherosclerotic cardiovascular disease, including heart attack, is the leading cause of death in the United States. A large proportion of cardiovascular risk is heritable through known (e.g. lipids, blood pressure) and undiscovered mechanisms. Dr. Natarajan leverages natural human genetic variation, biomarkers, human physiology, and digital health to: 1) understand the biology of atherosclerosis in humans; 2) identify new therapeutic targets to reduce cardiovascular risk; 3) predict risk for developing a heart attack; and 4) identify individuals who may benefit from tailored preventive strategies.